|Day Low/High||111.54 / 115.48|
|52 Wk Low/High||55.00 / 133.62|
Incyte Corporation (Nasdaq: INCY) (the "Company") today announced the pricing of its underwritten public offering of 4,945,000 shares of its common stock.
Incyte Corporation (Nasdaq: INCY) (the "Company") today announced that the Company intends to offer to sell, subject to market and other conditions, 4,945,000 shares of its common stock in an underwritten public offering.
Incyte Corporation (NASDAQ:INCY) is proud to recognize and support the patients of the MPN community throughout September in honor of Blood Cancer Awareness Month.
Incyte Corporation (Nasdaq:INCY) today announced that the European Society for Medical Oncology (ESMO) has published an abstract (#1214O) containing new and updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating...
Buying's good for the acquirers, which should give other companies ideas.
The San Diego firm said a Phase 3 study of Otividex in patients with Meniere's disease missed its primary endpoint.
Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 6th on Forbes magazine's 2017 list of the World's Most Innovative Companies.
Incyte Corporation (Nasdaq: INCY) today reports 2017 second-quarter financial results, highlighting strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.
Eli Lilly and Incyte gave an update on rheumatoid arthritis drug baricitinib as Lilly unveiled second-quarter numbers that surpassed analyst estimates.
Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in GRAVITAS-301, a pivotal Phase 3 trial for the first-line treatment of patients with acute graft-versus-host disease (GVHD).
'Blind side' competition is playing havoc with some highly visible companies, says Jim Cramer. You can't compete with free.
Jim Cramer's bullish on Alexion Pharmaceuticals and Incyte. But, he says, Disney's good for the long term.
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 10:00 a.
Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.
Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.
- Pooled analysis of eight clinical trials shows no difference in serious infection events compared to placebo
Jim Cramer is bullish on Domino's Pizza, Xylem, and Incyte, but he's waiting for better pricing for NXP Semiconductor.
Jim Cramer says the markets could be further rattled by the Federal Reserve meeting.
Lilly to share 31 abstracts, including 27 abstracts detailing safety, efficacy and patient outcomes data for Olumiant and Taltz
Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Goldman Sachs 38 th Annual Global Healthcare Conference on Wednesday,...
Credit Suisse analyst Alethia Young isn't worried about Incyte.
Incyte Corporation (Nasdaq:INCY) announced today that data from ongoing investigational studies of epacadostat in combination with pembrolizumab (ECHO-202) and nivolumab (ECHO-204) in multiple tumor types will be discussed...
Incyte Corporation (Nasdaq:INCY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced updated data from the ongoing Phase 1/2 ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte's investigational...
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated data from the ongoing Phase 1/2 ECHO-202 trial evaluating epacadostat, Incyte's...
Incyte's actions are another reminder that biotech companies carefully groom and manage the clinical data they want investors to see, even at important, open medical meetings like ASCO.
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced updated data from the advanced non-small cell lung cancer (NSCLC) patient cohort of the ongoing Phase...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.